drugset / Trial / NCT01193296

Glycemic Holter Study (Continuous Glucose Monitoring) -

NCT01193296

Phase 4 Completed 36 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will assess glycemic variability and optimized glycemic control in T2DM patients treated with a DPP-4 inhibitor as add-on therapy to metformin.

Timeline

Start
2010-06
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sitagliptin Small molecule
Subject Vildagliptin Other / unclassified